{
    "root": "30a0f998-8ec1-e7d1-e063-6394a90ad7e2",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Omeprazole",
    "value": "20250318",
    "ingredients": [
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "CETYL ALCOHOL",
            "code": "936JST6JCN"
        },
        {
            "name": "SODIUM PHOSPHATE, DIBASIC, DIHYDRATE",
            "code": "94255I6E2T"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "HYPROMELLOSE PHTHALATE (31% PHTHALATE, 40 CST)",
            "code": "G4U024CQK6"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "OMEPRAZOLE",
            "code": "KG60484QX9"
        }
    ],
    "indications": "omeprazole delayed-release capsules proton pump inhibitor ( ppi ) indicated : treatment active duodenal ulcer adults ( 1.1 ) eradication helicobacter pylori reduce risk duodenal ulcer recurrence adults ( 1.2 ) treatment active benign gastric ulcer adults ( 1.3 ) treatment symptomatic gastroesophageal reflux disease ( gerd ) patients 2 years age older ( 1.4 ) maintenance healing ee due acid-mediated gerd patients 2 years age older ( 1.6 ) pathologic hypersecretory conditions adults ( 1.7 )",
    "contraindications": "indication recommended adult ( 2.1 ) pediatric ( 2.2 ) treatment active duodenal ulcer 20 mg daily 4 weeks ; patients may require additional 4 weeks ( 2.1 ) h. pylori eradication reduce risk duodenal ulcer recurrence triple therapy : omeprazole 20 mg twice daily 10 days ( 2.1 ) 1 amoxicillin 1000 mg clarithromycin 500 mg dual therapy : omeprazole 40 mg daily 14 days 2 clarithromycin 500 mg three times daily 14 days ( 2.1 ) active benign gastric ulcer 40 mg daily 4 8 weeks ( 2.1 ) symptomatic gerd 20 mg daily 4 weeks ( 2.1 ) full prescribing information weight based dosing pediatric patients 2 years age older ( 2.2 ) ee due acid-mediated gerd 20 mg daily 4 8 weeks ( 2.1 ) 3 full prescribing information weight based dosing pediatric patients 2 years age older ( 2.2 ) maintenance healing ee due acid-mediated gerd 20 mg daily ( 2.1 ) 3 full prescribing information weight based dosing pediatric patients 2 years age older ( 2.2 ) pathological hypersecretory conditions starting dose 60 mg daily ( varies individual patient , full prescribing information ) long clinically indicated ( 2.1 ) 1. ulcer present , continue omeprazole 20 mg daily additional 18 days . 2. ulcer present , continue omeprazole 20 mg daily additional 14 days . 3. additional 4 weeks treatment may given response ; recurrence additional 4 8 week courses may considered . 4. studied 12 months . reduce 10 mg daily patients hepatic impairment ( child-pugh class , b , c ) asian patients ( 8.6 , 8.7 )",
    "warningsAndPrecautions": "omeprazole delayed-release capsules , usp 20 mg size ‘ 2 ’ two piece hard gelatin capsules light blue blue body “ g ” imprinted black ink light blue blue cap “ g231 ” imprinted black ink . capsules filled white off-white pellets . supplied follows : ndc : 70518-2251-00 ndc : 70518-2251-01 ndc : 70518-2251-02 ndc : 70518-2251-03 ndc : 70518-2251-04 packaging : 30 1 blister pack packaging : 14 1 bottle plastic packaging : 90 1 bottle plastic packaging : 100 1 box packaging : 1 1 pouch storage store omeprazole delayed-release capsules tight container protected light moisture . store 20°c 25°c ( 68°f 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "omeprazole delay-release capsules contraindicated patients known hypersensitivity including anaphylaxis formulation substituted benzimidazol . hypersensitivity may include anaphylaxis , anaphylactic shock , angioedema , bronchospasm , acute tubulointerstitial nephritis , urticaria [ ( 5.2 ) , ( 6 ) ] . proton pump inhibitors ( ppis ) , including omeprazole , contraindicated patients receiving rilpivirine-containing products [ ( 7 ) ] . information antibacterial agents ( clarithromycin amoxicillin ) indicated combination omeprazole , refer section package inserts .",
    "indications_original": "Omeprazole delayed-release capsules are a proton pump inhibitor (PPI) indicated for the: Treatment of active duodenal ulcer in adults ( 1.1 ) Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults ( 1.2 ) Treatment of active benign gastric ulcer in adults ( 1.3 ) Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 2 years of age and older ( 1.4 ) Maintenance of healing of EE due to acid-mediated GERD in patients 2 years of age and older ( 1.6 ) Pathologic hypersecretory conditions in adults ( 1.7 )",
    "contraindications_original": "Indication Recommended Adult ( 2.1 ) and Pediatric Dosage ( 2.2 ) Treatment of Active Duodenal Ulcer 20 mg once daily for 4 weeks; some patients may require an additional 4 weeks (2.1) H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Omeprazole 20 mg Each drug twice daily for 10 days (2.1) 1 Amoxicillin 1000 mg Clarithromycin 500 mg Dual Therapy: Omeprazole 40 mg once daily for 14 days 2 Clarithromycin 500 mg three times daily for 14 days (2.1) Active Benign Gastric Ulcer 40 mg once daily for 4 to 8 weeks (2.1) Symptomatic GERD 20 mg once daily for up to 4 weeks (2.1) See full prescribing information for weight based dosing in pediatric patients 2 years of age and older (2.2) EE due to Acid-Mediated GERD 20 mg once daily for 4 to 8 weeks (2.1) 3 See full prescribing information for weight based dosing in pediatric patients 2 years of age and older (2.2) Maintenance of Healing of EE due to Acid-Mediated GERD 20 mg once daily (2.1) 3 See full prescribing information for weight based dosing in pediatric patients 2 years of age and older (2.2) Pathological Hypersecretory Conditions Starting dose is 60 mg once daily (varies with individual patient, see full prescribing information) as long as clinically indicated (2.1) 1. if ulcer present, continue Omeprazole 20 mg once daily for an additional 18 days. 2. if ulcer present, continue Omeprazole 20 mg once daily for an additional 14 days. 3. an additional 4 weeks of treatment may be given if no response; if recurrence additional 4 to 8 week courses may be considered. 4. studied for 12 months. Reduce the dosage to 10 mg once daily for patients with hepatic impairment (Child-Pugh Class A, B, or C) and Asian patients ( 8.6 , 8.7 )",
    "warningsAndPrecautions_original": "Omeprazole Delayed-Release Capsules, USP 20 mg are size ‘2’ two piece hard gelatin capsules with a light blue to blue body with “G” imprinted in black ink and a light blue to blue cap with “G231” imprinted in black ink. The capsules are filled with white to off-white pellets. They are supplied as follows:\n                  \n                  \n                  \n                  NDC: 70518-2251-00\n                  NDC: 70518-2251-01\n                  NDC: 70518-2251-02\n                  NDC: 70518-2251-03\n                  NDC: 70518-2251-04\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 14 in 1 BOTTLE PLASTIC\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  PACKAGING: 100 in 1 BOX \n                  PACKAGING: 1 in 1 POUCH \n                  \n                  \n                  \n                  \n                  Storage\n                  Store Omeprazole Delayed-Release Capsules in a tight container protected from light and moisture. Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].\n                  \n                  \n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Omeprazole delay-release capsules are contraindicated in patients with known hypersensitivity reactions including anaphylaxis to the formulation or any substituted benzimidazol. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria\n  \n   [see Warnings and Precautions (\n   \n    5.2), Adverse Reactions (\n   \n    6)]\n  \n   .\n \n  \n                     Proton pump inhibitors (PPIs), including omeprazole, are contraindicated in patients receiving rilpivirine-containing products\n  \n   [see Drug Interactions (\n   \n    7)].\n  \n   \n                     \n                     For information about contraindications of antibacterial agents (clarithromycin and amoxicillin) indicated in combination with omeprazole, refer to the CONTRAINDICATIONS section of their package inserts."
}